Reported 5 months ago
A recent article by The Motley Fool discusses the potential for a 29% increase in Medtronic's stock price, backed by a positive rating from Wells Fargo analyst Larry Biegelsen. Despite recent fluctuations in the stock following quarterly results, the article highlights the company's strong dividend program, with a 3.4% yield and consistent quarterly payment increases for 47 years. Medtronic's focus on innovative medical devices, recent FDA approvals, and partnerships like the one with Nvidia for an AI platform indicate positive growth prospects. While the stock may be trading at a fair price, it could be a good addition for income-seeking investors looking for long-term gains.
Source: YAHOO